Researchers track Real-World results of prostate cancer drug combo

NCT ID NCT06661122

Recruiting now Knowledge-focused Sponsor: Bayer Source: ClinicalTrials.gov ↗

Summary

This study is collecting and reviewing the medical records of 100 Japanese men with a specific type of prostate cancer that has spread to a few bones. The men are already receiving a three-drug treatment (darolutamide, hormone therapy, and chemotherapy) as part of their normal care. The goal is to learn more about how safe and effective this drug combination is in everyday medical practice, without changing anyone's treatment plan.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Many locations

    RECRUITING

    Multiple Locations, Japan

Conditions

Explore the condition pages connected to this study.